English
 
Help Privacy Policy Disclaimer
  Advanced SearchBrowse
  1. View item / 
  2. Item Summary

Item

ITEM ACTIONSEXPORT
Add to Basket
  Local TagsRelease HistoryDetailsSummary

Released
Journal Article

Alzheimer’s disease FDG PET imaging pattern in an amyloid-negative mild cognitive impairment subject

MPS-Authors
/persons/resource/persons19981

Schroeter,  Matthias L.
Clinic for Cognitive Neurology, University of Leipzig, Germany;
Department Neurology, MPI for Human Cognitive and Brain Sciences, Max Planck Society;
Leipzig Research Center for Civilization Diseases (LIFE), University of Leipzig, Germany;

External Resource
No external resources are shared
Fulltext (restricted access)
There are currently no full texts shared for your IP range.
Fulltext (public)
There are no public fulltexts stored in PuRe
Supplementary Material (public)
There is no public supplementary material available
Citation

Tiepolt, S., Patt, M., Hoffmann, K.-T., Schroeter, M. L., Sabri, O., & Barthel, H. (2015). Alzheimer’s disease FDG PET imaging pattern in an amyloid-negative mild cognitive impairment subject. Journal of Alzheimer's Disease, 47(3), 539-543. doi:10.3233/JAD-150163.


Cite as: https://hdl.handle.net/11858/00-001M-0000-0029-ACB8-6
Abstract
The revised NIA-AA diagnostic criteria for Alzheimer’s disease (AD) and mild cognitive impairment (MCI) due to AD make use of amyloid pathology and neurodegeneration biomarkers which increase the diagnostic confidence in the majority of patients. However, in daily praxis, cases with conflicting biomarker constellations occur. A MCI subject underwent neuropsychological testing supplemented by FDG and amyloid PET/MRI as well as CSF sampling. In this subject, the biomarkers of Aβ deposition were negative. [18F]FDG PET, however, showed an AD-typical hypometabolism. Further studies are required to determine frequency and relevance of cases with neurodegeneration-first biomarker constellations to improve our understanding on pathogenesis and diagnosis of AD.